Valuation: Dermata Therapeutics, Inc.

Market Cap 3.07M 2.76M 2.52M 2.3M 4.34M 289M 4.48M 30.39M 12.17M 154M 11.53M 11.29M 487M P/E 2026 *
-0.35x
P/E 2027 * -0.53x
Enterprise Value 3.07M 2.76M 2.52M 2.3M 4.34M 289M 4.48M 30.39M 12.17M 154M 11.53M 11.29M 487M EV / Sales 2026 *
30.7x
EV / Sales 2027 * 4.1x
Free-Float
77.8%
Yield 2026 *
-
Yield 2027 * -
1 day+0.28%
1 week-1.42%
Current month-1.42%
1 month-32.39%
3 months-31.17%
6 months-39.84%
Current year-67.07%
1 week 0.72
Extreme 0.7201
0.91
1 month 0.6
Extreme 0.6032
1.18
Current year 0.6
Extreme 0.6032
4.66
1 year 0.6
Extreme 0.6032
4.66
3 years 0.6
Extreme 0.6032
146.25
5 years 0.6
Extreme 0.6032
14,222.87
10 years 0.6
Extreme 0.6032
16,679.99
Manager TitleAgeSince
Chief Executive Officer 67 2014-12-07
Director of Finance/CFO 48 2021-08-31
Investor Relations Contact - -
Director TitleAgeSince
Chairman 67 2021-03-31
Director/Board Member 77 2014-12-07
Director/Board Member 78 2016-09-19
Date Insider Type Main position Quantity % Market Cap. Importance
8/16/26 Free

Chief Financial Officer

306,120 10.7966%
2/17/26 Buy

General Counsel

1,000 0.0353%
1/2/26 Free

Director

2,500 0.0940%
Change 5-day change 1-year change 3-year change Capi.($)
+0.28%-1.42%-74.10%-99.39% 3.07M
-4.83%+3.51%+53.62%+61.75% 65.94B
-1.34%+2.98%+24.79%+100.18% 56.53B
+0.02%+1.07%+10.63%+76.66% 56.88B
+5.09%+9.89%+22.45%+107.48% 46.49B
+2.62%+1.68%+28.91%+37.01% 44.8B
+8.24%+0.51%+213.26%+792.66% 41.59B
-1.86%+10.13%+26.82%+53.22% 35.35B
-2.97%-9.84%+88.86%+76.17% 33.29B
-2.18%+7.06%+36.06%-4.95% 24.92B
Average +0.31%+2.78%+43.13%+120.08% 40.58B
Weighted average by Cap. +0.21%+3.40%+53.12%+142.95%

Financials

2026 *2027 *
Net sales 100K 89.76K 82K 74.91K 141K 9.39M 146K 989K 396K 5.01M 375K 367K 15.84M 750K 673K 615K 562K 1.06M 70.43M 1.09M 7.42M 2.97M 37.6M 2.81M 2.75M 119M
Net income -11.08M -9.95M -9.09M -8.3M -15.66M -1.04B -16.15M -110M -43.89M -556M -41.6M -40.71M -1.76B -13.78M -12.37M -11.3M -10.33M -19.47M -1.29B -20.08M -136M -54.58M -691M -51.73M -50.62M -2.18B
Net Debt - -
Projected Income Statement - Annual - Dermata Therapeutics, Inc.
Logo Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.
Employees
9
Date Price Change Volume
26-11-06 US$0.7640 +0.28% 60,213
26-11-05 US$0.7619 -10.87% 50,624
26-11-04 US$0.8548 +0.72% 51,986
26-11-03 US$0.8487 +12.59% 226,043
26-11-02 US$0.7538 -2.74% 141,372
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.7640USD
Average target price
4.000USD
Spread / Average Target
+423.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermata Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DRMA Stock